MELEMA and Lonza Enter into a Development Services Agreement to Further Progress MELEMA’s Cancer Therapeutic, ME-503
Hamburg, Germany and Basel, Switzerland, 21 July 2015 – Lonza and MELEMA Pharma GmbH announced today that they have entered into a service agreement for protein assessment services on MELEMA’s leading cancer therapeutic, ME-503. Under the agreement, Lonza will investigate the strong ME-503 induced DC stimulation and T cell responses. Analysis of T cell responses is a frequently used tool to monitor the activation of the immune system.
Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life. Further information can be found at www.lonza.com.